Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Aigen Investment Management LP

Aigen Investment Management LP lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 81.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,823 shares of the biotechnology company’s stock after selling 7,994 shares during the quarter. Aigen Investment Management LP’s holdings in Sarepta Therapeutics were worth $228,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in SRPT. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $607,000. Teachers Retirement System of The State of Kentucky purchased a new position in Sarepta Therapeutics during the 2nd quarter valued at about $4,771,000. Securian Asset Management Inc. purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $1,187,000. Natixis Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the second quarter worth $1,918,000. Finally, Edgestream Partners L.P. purchased a new position in Sarepta Therapeutics in the 1st quarter valued at about $627,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Raymond James reiterated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Piper Sandler cut their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. UBS Group boosted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They set a “buy” rating and a $165.00 price objective for the company. Finally, Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Buy” and a consensus price target of $181.33.

Sarepta Therapeutics Stock Down 4.2 %

Shares of SRPT opened at $104.54 on Friday. The firm has a market cap of $9.99 billion, a P/E ratio of 83.63 and a beta of 0.81. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 52 week low of $78.67 and a 52 week high of $173.25. The firm’s 50-day simple moving average is $123.72 and its 200 day simple moving average is $132.36.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.